What question did this study set out to answer?

This research aims to evaluate the effectiveness of recombinant ADAMTS13 in enhancing clinical outcomes for thrombotic thrombocytopenic purpura.

April 6, 2026

Recombinant ADAMTS13 in thrombotic thrombocytopenic purpura: a systematic review and meta-analysis

Key Points

This research aims to evaluate the effectiveness of recombinant ADAMTS13 in enhancing clinical outcomes for thrombotic thrombocytopenic purpura.
Conducted a systematic review and meta-analysis of randomized controlled trials
Evaluated ADAMTS13 activity and clinical outcomes in thrombotic thrombocytopenic purpura
Assessed the certainty of evidence using GRADE methodology.
rADAMTS13 significantly improves ADAMTS13 activity
No significant improvement in key clinical outcomes was found
Findings are based on two trials with moderate to low certainty.

Abstract

rADAMTS13 significantly enhances ADAMTS13 activity but did not demonstrate a significant improvement in key clinical outcomes. These findings, based on two RCTs, are of moderate to low certainty per GRADE assessment. Larger trials are needed to confirm the clinical benefits of rADAMTS13.

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Discussion

Authors

Anaya Abdul Samad

S. Qureshi

Bolan University of Medical and Health Sciences

Akif Shahid Khan

Khyber Medical College

Journals

Blood Coagulation & Fibrinolysis

Actions

Institutions

Karolinska Institutet

Central South University

SUNY Downstate Health Sciences University

References and Citations

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Recombinant ADAMTS13 in thrombotic thrombocytopenic purpura: a systematic review and meta-analysis

Key Points

Abstract

Citation Network

Connected Papers

Discussion

Authors

Journals

Actions

Institutions

References and Citations

Citation Network

Connected Papers

Discussion

Cite this study

Also consider

Also consider